Ivantis initiates enrollment in Hydrus Microstent study for open angle glaucoma

Ivantis announced the enrollment of the first patient in the Hydrus IV study today. The Hydrus Microstent is the world's first intracanalicular scaffold for treatment of primary open angle glaucoma, a disease that afflicts over 70 million people worldwide and approximately 3 million people in the United States.

Full Story →